Cargando…
Molecular triaging options for women testing HPV positive with self-collected samples
We review developments in molecular triaging options for women who test positive for high-risk human papillomavirus (hrHPV) on self-collected samples in the context of cervical cancer elimination. The World Health Organization (WHO) recommends hrHPV screening as the primary test for cervical screeni...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10560038/ https://www.ncbi.nlm.nih.gov/pubmed/37810963 http://dx.doi.org/10.3389/fonc.2023.1243888 |
_version_ | 1785117642084843520 |
---|---|
author | Taghavi, Katayoun Zhao, Fanghui Downham, Laura Baena, Armando Basu, Partha |
author_facet | Taghavi, Katayoun Zhao, Fanghui Downham, Laura Baena, Armando Basu, Partha |
author_sort | Taghavi, Katayoun |
collection | PubMed |
description | We review developments in molecular triaging options for women who test positive for high-risk human papillomavirus (hrHPV) on self-collected samples in the context of cervical cancer elimination. The World Health Organization (WHO) recommends hrHPV screening as the primary test for cervical screening due to its high sensitivity compared to other screening tests. However, when hrHPV testing is used alone for treatment decisions, a proportion of women of childbearing age receive unnecessary treatments. This provides the incentive to optimize screening regimes to minimize the risk of overtreatment in women of reproductive age. Molecular biomarkers can potentially enhance the accuracy and efficiency of screening and triage. HrHPV testing is currently the only screening test that allows triage with molecular methods using the same sample. Additionally, offering self-collected hrHPV tests to women has been reported to increase screening coverage. This creates an opportunity to focus health resources on linking screen-positive women to diagnosis and treatment. Adding an additional test to the screening algorithm (a triage test) may improve the test’s positive predictive value (PPV) and offer a better balance of benefits and risks for women. Conventional triage methods like cytology and visual inspection with acetic acid (VIA) cannot be performed on self-collected samples and require additional clinic visits and subjective interpretations. Molecular triaging using methods like partial and extended genotyping, methylation tests, detection of E6/E7 proteins, and hrHPV viral load in the same sample as the hrHPV test may improve the prediction of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) and invasive cancer, offering more precise, efficient, and cost-effective screening regimes. More research is needed to determine if self-collected samples are effective and cost-efficient for diverse populations and in comparison to other triage methods. The implementation of molecular triaging could improve screening accuracy and reduce the need for multiple clinical visits. These important factors play a crucial role in achieving the global goal of eliminating cervical cancer as a public health problem. |
format | Online Article Text |
id | pubmed-10560038 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-105600382023-10-08 Molecular triaging options for women testing HPV positive with self-collected samples Taghavi, Katayoun Zhao, Fanghui Downham, Laura Baena, Armando Basu, Partha Front Oncol Oncology We review developments in molecular triaging options for women who test positive for high-risk human papillomavirus (hrHPV) on self-collected samples in the context of cervical cancer elimination. The World Health Organization (WHO) recommends hrHPV screening as the primary test for cervical screening due to its high sensitivity compared to other screening tests. However, when hrHPV testing is used alone for treatment decisions, a proportion of women of childbearing age receive unnecessary treatments. This provides the incentive to optimize screening regimes to minimize the risk of overtreatment in women of reproductive age. Molecular biomarkers can potentially enhance the accuracy and efficiency of screening and triage. HrHPV testing is currently the only screening test that allows triage with molecular methods using the same sample. Additionally, offering self-collected hrHPV tests to women has been reported to increase screening coverage. This creates an opportunity to focus health resources on linking screen-positive women to diagnosis and treatment. Adding an additional test to the screening algorithm (a triage test) may improve the test’s positive predictive value (PPV) and offer a better balance of benefits and risks for women. Conventional triage methods like cytology and visual inspection with acetic acid (VIA) cannot be performed on self-collected samples and require additional clinic visits and subjective interpretations. Molecular triaging using methods like partial and extended genotyping, methylation tests, detection of E6/E7 proteins, and hrHPV viral load in the same sample as the hrHPV test may improve the prediction of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) and invasive cancer, offering more precise, efficient, and cost-effective screening regimes. More research is needed to determine if self-collected samples are effective and cost-efficient for diverse populations and in comparison to other triage methods. The implementation of molecular triaging could improve screening accuracy and reduce the need for multiple clinical visits. These important factors play a crucial role in achieving the global goal of eliminating cervical cancer as a public health problem. Frontiers Media S.A. 2023-09-22 /pmc/articles/PMC10560038/ /pubmed/37810963 http://dx.doi.org/10.3389/fonc.2023.1243888 Text en Copyright © 2023 Taghavi, Zhao, Downham, Baena and Basu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Taghavi, Katayoun Zhao, Fanghui Downham, Laura Baena, Armando Basu, Partha Molecular triaging options for women testing HPV positive with self-collected samples |
title | Molecular triaging options for women testing HPV positive with self-collected samples |
title_full | Molecular triaging options for women testing HPV positive with self-collected samples |
title_fullStr | Molecular triaging options for women testing HPV positive with self-collected samples |
title_full_unstemmed | Molecular triaging options for women testing HPV positive with self-collected samples |
title_short | Molecular triaging options for women testing HPV positive with self-collected samples |
title_sort | molecular triaging options for women testing hpv positive with self-collected samples |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10560038/ https://www.ncbi.nlm.nih.gov/pubmed/37810963 http://dx.doi.org/10.3389/fonc.2023.1243888 |
work_keys_str_mv | AT taghavikatayoun moleculartriagingoptionsforwomentestinghpvpositivewithselfcollectedsamples AT zhaofanghui moleculartriagingoptionsforwomentestinghpvpositivewithselfcollectedsamples AT downhamlaura moleculartriagingoptionsforwomentestinghpvpositivewithselfcollectedsamples AT baenaarmando moleculartriagingoptionsforwomentestinghpvpositivewithselfcollectedsamples AT basupartha moleculartriagingoptionsforwomentestinghpvpositivewithselfcollectedsamples |